Amgen’s Next Generation Biomanufacturing Facility

Over past decades, the biopharma industry’s emphasis has been on optimizing traditional cell culture platforms using stainless steel bioreactors to manufacture proteins. At Amgen, we’ve taken a different approach by investing in Amgen’s Next Generation Biomanufacturing. The facility at Amgen Singapore is our first investment in next-generation flexible manufacturing. I will illustrate the facility’s new design concepts and discuss the speed at which the facility was constructed. The result is a highly reconfigurable manufacturing facility that requires little or no retrofit, beyond specific new unit operations, to accommodate new product introductions.